ABX464 + Placebo
Phase 2/3Withdrawn 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Crohn Disease
Conditions
Crohn Disease
Trial Timeline
Sep 19, 2022 → Sep 19, 2022
NCT ID
NCT03905109About ABX464 + Placebo
ABX464 + Placebo is a phase 2/3 stage product being developed by Abivax for Crohn Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03905109. Target conditions include Crohn Disease.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05535946 | Phase 3 | Active |
| NCT05507216 | Phase 3 | Completed |
| NCT05507203 | Phase 3 | Completed |
| NCT03905109 | Phase 2/3 | Withdrawn |
| NCT05032560 | Phase 1 | Completed |
| NCT04393038 | Phase 2/3 | Terminated |
| NCT02735863 | Phase 2 | Completed |
Competing Products
20 competing products in Crohn Disease